Five-drug combination targets aggressive B-cell lymphomas
Jun 19, 2024 · The five-drug combination targets multiple molecular pathways that diffuse large B-cell lymphoma (DLBCL) tumors use to survive. In a clinical trial at NIH’s National Cancer Institute (NCI), researchers tested the combination of venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide (called ViPOR) in 50 patients with DLBCL, the most ...
Atezolizumab-Based Triplet Regimen Shows Activity in DLBCL …
2 days ago · Treatment of diffuse large B-cell lymphoma (DLBCL) with Richter transformation (RT) with atezolizumab plus venetoclax and obinutuzumab demonstrated promising activity with a manageable safety ...
Yescarta for Relapsed or Refractory Large B-Cell Lymphoma
Jul 10, 2023 · The CAR T-cell therapy axicabtagene ciloleucel (Yescarta) improved survival for people with large B-cell lymphoma that was not responding to initial treatment or had relapsed quickly, according to new data from the ZUMA-7 trial.
Trial of cell-based therapy for high-risk lymphoma leads to FDA ...
Jul 9, 2024 · CAR-T cell therapy was first approved by the FDA as a treatment for relapsed or treatment-resistant diffuse large B-cell lymphoma and for children and young adults under 25 with acute lymphoblastic leukemia.
Treatment and outcomes for patients with relapsed or refractory diffuse …
Jan 4, 2024 · Diffuse large B-cell lymphoma (DLBCL) is a common and aggressive form of non-Hodgkin lymphoma primarily affecting adults. The introduction of rituximab―a monoclonal antibody that...
Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma
Jun 19, 2024 · The identification of oncogenic mutations in diffuse large B-cell lymphoma (DLBCL) has led to the development of drugs that target essential survival pathways, but whether targeting...
FDA Approves New Treatment For Adults With Relapsed Or Refractory Large ...
Feb 5, 2021 · Today, the U.S. Food and Drug Administration approved Breyanzi (lisocabtagene maraleucel), a cell-based gene therapy to treat adult patients with certain types of large B-cell lymphoma who have...
Diffuse Large B-Cell Lymphoma: FDA Updates
Apr 19, 2023 · Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL) in the United States and worldwide, accounting for up to one-third of patients with newly diagnosed NHL in the United States.
Diffuse Large B-Cell Lymphoma | New England Journal of …
Mar 3, 2021 · Large B-cell lymphomas, with an estimated 150,000 new cases annually worldwide, represent almost 30% of all cases of non-Hodgkin’s lymphoma. Patients typically present with progressive...
2024 Update: Advances in the risk stratification and management …
Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease with varying clinical outcomes. Our understanding of its molecular makeup continues to improve risk stratification, and artificial-intelligence and ctDNA-based analyses have the potential to enhance risk assessment and disease monitoring.